Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Sep;54(3):567-74.
doi: 10.1161/HYPERTENSIONAHA.109.132522. Epub 2009 Jul 20.

Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk: Effects of acetyl-L-carnitine Therapy

Affiliations
Clinical Trial

Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk: Effects of acetyl-L-carnitine Therapy

Piero Ruggenenti et al. Hypertension. .

Abstract

Insulin resistance, a key component of the metabolic syndrome, is a risk factor for diabetes mellitus and cardiovascular disease. Acetyl-L-carnitine infusion acutely ameliorated insulin sensitivity in type 2 diabetics with insulin resistance. In this sequential off-on-off pilot study, we prospectively evaluated the effects of 24-week oral acetyl-L-carnitine (1 g twice daily) therapy on the glucose disposal rate (GDR), assessed by hyperinsulinemic euglycemic clamps, and components of the metabolic syndrome in nondiabetic subjects at increased cardiovascular risk a priori segregated into 2 groups with GDR < or =7.9 (n=16) or >7.9 (n=16) mg/kg per minute, respectively. Baseline GDR and systolic blood pressure were negatively correlated (n=32; P=0.001; r=-0.545), and patients with GDR < or =7.9 mg/kg per minute had higher systolic/diastolic blood pressure than those with higher GDR. Acetyl-L-carnitine increased GDR from 4.89+/-1.47 to 6.72+/-3.12 mg/kg per minute (P=0.003, Bonferroni-adjusted) and improved glucose tolerance in patients with GDR < or =7.9 mg/kg per minute, whereas it had no effects in those with higher GDRs. Changes in GDR were significantly different between groups (P=0.017, ANCOVA). Systolic blood pressure decreased from 144.0+/-13.6 to 135.1+/-8.4 mm Hg and from 130.8+/-12.4 to 123.8+/-10.8 mm Hg in the lower and higher GDR groups, respectively (P<0.05 for both; P<0.001 overall) and progressively recovered toward baseline over 8 weeks posttreatment. Total and high molecular weight adiponectin levels followed specular trends. Diastolic blood pressure significantly decreased only in those with higher GDRs. Treatment was well tolerated in all of the patients. Acetyl-L-carnitine safely ameliorated arterial hypertension, insulin resistance, impaired glucose tolerance, and hypoadiponectinemia in subjects at increased cardiovascular risk. Whether these effects may translate into long-term cardioprotection is worth investigating.

Trial registration: ClinicalTrials.gov NCT00393770.

Comment in

  • Hypertension and insulin resistance.
    Whaley-Connell A, Sowers JR. Whaley-Connell A, et al. Hypertension. 2009 Sep;54(3):462-4. doi: 10.1161/HYPERTENSIONAHA.109.134460. Epub 2009 Jul 27. Hypertension. 2009. PMID: 19635987 Free PMC article. No abstract available.
  • Oral carnitine therapy and insulin resistance.
    Muniyappa R. Muniyappa R. Hypertension. 2010 Feb;55(2):e13. doi: 10.1161/HYPERTENSIONAHA.109.147504. Epub 2009 Dec 14. Hypertension. 2010. PMID: 20008672 No abstract available.

Similar articles

See all similar articles

Cited by 29 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback